Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company based in Espoo, Finland, dedicated to developing disease-modifying therapies for neurodegenerative diseases. The company's mission is to halt or reverse the progression of these debilitating conditions, addressing significant unmet medical needs.

The company's primary focus is on Parkinson's disease, with its lead product candidate being HER-096. HER-096 is a CDNF-derived peptidomimetic molecule designed to mimic the neuroprotective activity of the Cerebral Dopamine Neurotrophic Factor (CDNF) protein. This innovative therapy aims to target the underlying mechanisms of Parkinson's disease, including proteostasis imbalance, mitochondrial dysfunction, and neuroinflammation, through the modulation of the unfolded protein response (UPR). HER-096 is developed for convenient subcutaneous administration.

Recent notable developments include positive feedback from the U.S. Food and Drug Administration (FDA) and the finalization of the Phase 2a study design for HER-096 in June 2026. The company also appointed Dr. Juha Savola as Chief Medical Officer in June 2026. In October 2025, Herantis Pharma successfully completed its Phase 1b trial for HER-096, demonstrating its safety, tolerability, and ability to penetrate the blood-brain barrier in Parkinson's patients. The company has secured an €8 million Horizon Europe grant to support the upcoming Phase 2 trial. Antti Vuolanto serves as the CEO.